Karen McNeely
Psychiatric/Mental Health · Jacksonville, FLNPI 1285778423
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Idorsia Pharmaceuticals US Inc at 57.7% of the total. Reporting peaked in 2023 at $8,202 and has fallen 84.7% since, to $1,256 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $147.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$8K
- Johnson & Johnson$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$893
- Axsome Therapeutics, Inc.$676
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$578
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$6,15047%
- Travel & lodging$1,1118%
- Food & beverage$5,84844%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 16 | $7,597 |
| Johnson & Johnson | 15 | $1,264 |
| AbbVie | 19 | $1,076 |
| Otsuka America Pharmaceutical, Inc. | 12 | $893 |
| Axsome Therapeutics, Inc. | 6 | $676 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $578 |
| Jazz Pharmaceuticals Inc. | 1 | $145 |
| Tris Pharma Inc | 2 | $140 |
| Avanir Pharmaceuticals, Inc. | 2 | $134 |
| Alkermes, Inc. | 1 | $124 |
| Neurocrine Biosciences, Inc. | 1 | $123 |
| LEO Pharma Inc. | 1 | $123 |
| Braeburn Inc. | 1 | $108 |
| Vanda Pharmaceuticals Inc. | 1 | $93 |
| Lundbeck LLC | 2 | $33 |
| Lilly USA, LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$7,421
- Auvelity$579
- SPRAVATO$503
- INVEGA SUSTENNA$488
- CAPLYTA$487
- VRAYLAR$484
- REXULTI$369
- ABILIFY MAINTENA$240
- XYWAV$145
- Dyanavel XR$124
- Quillivant$124
- Quillichew ER$124
- VIVITROL$124
- INGREZZA$123
- NUEDEXTA$111
- BRIXADI$108
- INVEGA TRINZA$106
How this compares
$13,156 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $25,444 |
| Lamotrigine ErLamotrigine | 22 | $3,855 |
| Aripiprazole | 38 | $3,201 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 38 | $2,923 |
| Duloxetine Hcl | 124 | $2,533 |
| Bupropion XlBupropion Hcl | 88 | $2,517 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 33 | $1,627 |
| Mirtazapine | 64 | $1,529 |
| Lamotrigine | 98 | $1,360 |
| Ziprasidone Hcl | 13 | $1,341 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 38 | $1,306 |
| Clozapine | 13 | $1,268 |
| Quetiapine Fumarate | 68 | $1,132 |
| Risperidone | 50 | $956 |
| Buspirone Hcl | 83 | $941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $893 | $25,44412 claims |
| Lilly USA, LLCOlanzapine | $26 | $59127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Jacksonville
- Bethanie Simmons BecilJacksonville$782K
- Roger RiveraKissimmee$1.6M
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.